DELFI DIAGNOSTICS
Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients.
DELFI DIAGNOSTICS
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2019-01-01
Address:
Baltimore, Maryland, United States
Country:
United States
Website Url:
http://www.delfidiagnostics.com
Total Employee:
101+
Status:
Active
Contact:
410-696-3304
Email Addresses:
[email protected]
Total Funding:
330.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Global Site Tag Nginx Sitelinks Search Box
Similar Organizations
Cofactor Genomics
Cofactor Genomics builds multidimensional models of disease to deliver true precision medicine.
Juno Diagnostics
Juno Diagnostics is a healthcare technology company developing the next generation cell-free DNA-based noninvasive prenatal test solutions.
LightDeck Diagnostics
LightDeck is a developer of on-the-spot diagnostic products used to offer fast, accurate, simple, and low-cost diagnostic tests.
Current Advisors List
Current Employees Featured
Founder
Investors List
PTX Capital
PTX Capital investment in Series B - Delfi Diagnostics
Northpond Ventures
Northpond Ventures investment in Series B - Delfi Diagnostics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series B - Delfi Diagnostics
Brown Advisory
Brown Advisory investment in Series B - Delfi Diagnostics
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - Delfi Diagnostics
Foresite Capital
Foresite Capital investment in Series B - Delfi Diagnostics
Point Field Partners
Point Field Partners investment in Series B - Delfi Diagnostics
OrbiMed
OrbiMed investment in Series B - Delfi Diagnostics
Rock Springs Capital
Rock Springs Capital investment in Series B - Delfi Diagnostics
T. Rowe Price
T. Rowe Price investment in Series B - Delfi Diagnostics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-12 | Jessica Meng Joins Delfi Diagnostics as Chief Commercial Officer |
| 2021-10-07 | Doug Schenkel Joins Delfi Diagnostics as Chief Financial Officer |
Official Site Inspections
http://www.delfidiagnostics.com Semrush global rank: 3.55 M Semrush visits lastest month: 4.11 K
- Host name: ec2-44-231-55-201.us-west-2.compute.amazonaws.com
- IP address: 44.231.55.201
- Location: Boardman United States
- Latitude: 45.8491
- Longitude: -119.7143
- Metro Code: 810
- Timezone: America/Los_Angeles
- Postal: 97818
More informations about "Delfi Diagnostics"
Our Mission - DELFI
General Inquiry: [email protected] Work with us: [email protected] 1810 Embarcadero Road, Suite 100 Palo Alto, CA 94303 2809 Boston Street, Suite 503 Baltimore, MD 21224See details»
Delfi Diagnostics - Crunchbase Company Profile
Contact Email [email protected] Phone Number 410-696-3304 Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests.See details»
Delfi Diagnostics Company Profile | Management and Employees List
Www.delfidiagnostics.com Delfi Diagnostics Profile and History Founded in 2019, Delfi Diagnostics is committed to developing high-performing, affordable blood tests for early detection of cancer …See details»
DELFI Diagnostics - LinkedIn
DELFI Diagnostics Biotechnology Research Baltimore, Maryland 15,767 followers Saving lives through early cancer detectionSee details»
Delfi Diagnostics - Overview, News & Similar companies - ZoomInfo
Jan 4, 2024 Delfi Diagnostics contact info: Phone number: (800) 589-2182 Website: www.delfidiagnostics.com What does Delfi Diagnostics do? Founded in 2019, Delfi …See details»
DELFI Diagnostics Appoints Susan Tousi as New Chief …
Jan 5, 2024 DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced the appointment of Susan Tousi as Chief Executive Officer.See details»
DELFI Diagnostics Announces Equity Investment from the Merck …
Jun 4, 2024 DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced an equity investment by the Merck …See details»
Delfi Diagnostics - Company Profile - Tracxn
Dec 4, 2024 Delfi Diagnostics - Provider of DNA sequencing for cancer detection. Raised a total funding of $332M over 4 rounds from 19 investors. Founded by Victor Velculescu in the year …See details»
Health Systems - DELFI
Let us help you take the next steps in improving your organization's patient care and resource allocation through next-generation blood-based tests and cfDNA testing. Schedule a Meeting ... [email protected] Work with us: …See details»
Working at Delfi Diagnostics - Glassdoor
Founded in 2019 by Victor Velculescu, a leader in cancer genomics, Delfi Diagnostics is committed to developing high-performing, affordable blood tests for early detection of cancer …See details»
Delfi Diagnostics Inc. | Scientist.com
Site Badges; DELFI Diagnostics 1810 Embarcadero RD, STE 100 Palo Alto, CA, 94303 United States: DELFI Diagnostics 2809 Boston St Baltimore, MD, 21224 United StatesSee details»
DELFI Diagnostics Company Overview, Contact Details
[email protected]: [email protected]: 30%. [email protected]: [email protected]: 1%. See more formats. …See details»
Delfi Diagnostics Selected as the Liquid Biopsy Partner for 4-IN …
Sep 19, 2022 Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as …See details»
Our Science - DELFI
General Inquiry: [email protected] Work with us: [email protected] 1810 Embarcadero Road, Suite 100 Palo Alto, CA 94303 2809 Boston Street, Suite 503 Baltimore, …See details»
DELFI Diagnostics Announces Availability of New Fragmentome …
Feb 1, 2024 DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's …See details»
Our People - DELFI
Earlier at Illumina, she led the product development organization as Chief Product Officer, and drove the acquisitions of three companies to scale up Illumina’s software solutions. ... General …See details»
DELFI Diagnostics Study on Cancer Treatment Monitoring Using ...
Oct 21, 2024 Today, DELFI Diagnostics, Inc., developer of accessible blood-based liquid biopsy tests that deliver a new way to enhance early cancer detection, is announcing the publication …See details»
Delfi Diagnostics raises $100M for a new approach to screening …
Jan 13, 2021 A new method of screening the blood for the telltale signs of tumors promises to offer more chances for a successful result, and Delfi Diagnostics has raised $100 million to …See details»
DELFI Diagnostics Working with Incendia Therapeutics to Employ …
Oct 28, 2024 DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced that Incendia Therapeutics will use …See details»